TRPM1
Transient receptor potential cation channel subfamily M member 1
Also known as: CSNB1C, LTRPC1, MLSN1, TRPM1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q7Z4N2
- Gene
- TRPM1
- Ensembl
- ENSG00000134160
- Chromosome
- 15
- Canonical length
- 1603 aa
- Protein class
- Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels
- Subcellular location
- Golgi apparatus,Plasma membrane,Centriolar satellite
OverviewNCBI Gene
This gene encodes a member of the transient receptor potential melastatin subfamily of transient receptor potential ion channels. The encoded protein is a calcium permeable cation channel that is expressed in melanocytes and may play a role in melanin synthesis. Specific mutations in this gene are the cause autosomal recessive complete congenital stationary night blindness-1C. The expression of this protein is inversely correlated with melanoma aggressiveness and as such it is used as a prognostic marker for melanoma metastasis. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2011]
Canonical amino-acid sequenceUniProt
1603 residues, UniProt reviewed canonical sequence.
>Q7Z4N2|TRPM1
1 MKDSNRCCCG QFTNQHIPPL PSATPSKNEE ESKQVETQPE KWSVAKHTQS YPTDSYGVLE
61 FQGGGYSNKA MYIRVSYDTK PDSLLHLMVK DWQLELPKLL ISVHGGLQNF EMQPKLKQVF
121 GKGLIKAAMT TGAWIFTGGV STGVISHVGD ALKDHSSKSR GRVCAIGIAP WGIVENKEDL
181 VGKDVTRVYQ TMSNPLSKLS VLNNSHTHFI LADNGTLGKY GAEVKLRRLL EKHISLQKIN
241 TRLGQGVPLV GLVVEGGPNV VSIVLEYLQE EPPIPVVICD GSGRASDILS FAHKYCEEGG
301 IINESLREQL LVTIQKTFNY NKAQSHQLFA IIMECMKKKE LVTVFRMGSE GQQDIEMAIL
361 TALLKGTNVS APDQLSLALA WNRVDIARSQ IFVFGPHWPP LGSLAPPTDS KATEKEKKPP
421 MATTKGGRGK GKGKKKGKVK EEVEEETDPR KIELLNWVNA LEQAMLDALV LDRVDFVKLL
481 IENGVNMQHF LTIPRLEELY NTRLGPPNTL HLLVRDVKKS NLPPDYHISL IDIGLVLEYL
541 MGGAYRCNYT RKNFRTLYNN LFGPKRPKAL KLLGMEDDEP PAKGKKKKKK KKEEEIDIDV
601 DDPAVSRFQY PFHELMVWAV LMKRQKMAVF LWQRGEESMA KALVACKLYK AMAHESSESD
661 LVDDISQDLD NNSKDFGQLA LELLDQSYKH DEQIAMKLLT YELKNWSNST CLKLAVAAKH
721 RDFIAHTCSQ MLLTDMWMGR LRMRKNPGLK VIMGILLPPT ILFLEFRTYD DFSYQTSKEN
781 EDGKEKEEEN TDANADAGSR KGDEENEHKK QRSIPIGTKI CEFYNAPIVK FWFYTISYLG
841 YLLLFNYVIL VRMDGWPSLQ EWIVISYIVS LALEKIREIL MSEPGKLSQK IKVWLQEYWN
901 ITDLVAISTF MIGAILRLQN QPYMGYGRVI YCVDIIFWYI RVLDIFGVNK YLGPYVMMIG
961 KMMIDMLYFV VIMLVVLMSF GVARQAILHP EEKPSWKLAR NIFYMPYWMI YGEVFADQID
1021 LYAMEINPPC GENLYDEEGK RLPPCIPGAW LTPALMACYL LVANILLVNL LIAVFNNTFF
1081 EVKSISNQVW KFQRYQLIMT FHDRPVLPPP MIILSHIYII IMRLSGRCRK KREGDQEERD
1141 RGLKLFLSDE ELKRLHEFEE QCVQEHFREK EDEQQSSSDE RIRVTSERVE NMSMRLEEIN
1201 ERETFMKTSL QTVDLRLAQL EELSNRMVNA LENLAGIDRS DLIQARSRAS SECEATYLLR
1261 QSSINSADGY SLYRYHFNGE ELLFEDTSLS TSPGTGVRKK TCSFRIKEEK DVKTHLVPEC
1321 QNSLHLSLGT STSATPDGSH LAVDDLKNAE ESKLGPDIGI SKEDDERQTD SKKEETISPS
1381 LNKTDVIHGQ DKSDVQNTQL TVETTNIEGT ISYPLEETKI TRYFPDETIN ACKTMKSRSF
1441 VYSRGRKLVG GVNQDVEYSS ITDQQLTTEW QCQVQKITRS HSTDIPYIVS EAAVQAEHKE
1501 QFADMQDEHH VAEAIPRIPR LSLTITDRNG MENLLSVKPD QTLGFPSLRS KSLHGHPRNV
1561 KSIQGKLDRS GHASSVSSLV IVSGMTAEEK KVKKEKASTE TECLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TRPM1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 6
- Mean surface accessibility (rSASA)
- 0.42
- Highest tissue expression
- 16 nTPM
Expression across tissuesHPA
Tissue
- retina: 16 nTPM
- skin: 4.6 nTPM
- testis: 2.1 nTPM
- spinal cord: 0.8 nTPM
- midbrain: 0.7 nTPM
- hippocampal formation: 0.3 nTPM
Single-cell type
- retinal bipolar cells: 276 nCPM
- retinal pigment epithelial cells: 205 nCPM
- melanocytes: 202 nCPM
- oligodendrocytes: 42 nCPM
- late primary spermatocytes: 9.7 nCPM
- early spermatids: 7.1 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- white matter: 0.9 nTPM
- midbrain: 0.8 nTPM
- spinal cord: 0.8 nTPM
- basal ganglia: 0.7 nTPM
- cerebral cortex: 0.6 nTPM
- cerebellum: 0.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about TRPM1.
Disease | AllUniProt
Conditions TRPM1 is implicated in, by any mechanism.
- Night blindness, congenital stationary, 1C (CSNB1C) MIM:613216
Disease | GeneticClinVar
115 pathogenic / likely-pathogenic of 1,431 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Congenital stationary night blindness 1C
- Congenital stationary night blindness
- Retinal dystrophy
- TRPM1-related disorder
- Retinal disorder
Disease | AutoantibodyPubMed
Conditions in which antibodies against TRPM1 are reported. Each links to that disease's full target list.
- Melanoma 7
Showing 1 of 3 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for TRPM1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
23 publications
- Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction.
2011 · PLoS One · RCR 2.7 · 76 citations - Anti-TRPM1 autoantibody-positive unilateral melanoma associated retinopathy (MAR) triggered by immunotherapy recapitulates functional and structural details of TRPM1-associated congenital stationary night blindness.
2024 · Am J Ophthalmol Case Rep · RCR 2.1 · 4 citations - Case report: Longitudinal evaluation and treatment of a melanoma-associated retinopathy patient.
2024 · Front Med (Lausanne) · RCR 1.7 · 2 citations - Unilateral cancer-associated retinopathy: diagnosis, serology and treatment.
2017 · Doc Ophthalmol · RCR 1.4 · 26 citations - Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice.
2013 · PLoS One · RCR 1.3 · 35 citations
Show 18 more
- CLINICAL COURSE OF PARANEOPLASTIC RETINOPATHY WITH ANTI-TRPM1 AUTOANTIBODY IN JAPANESE COHORT.
2019 · Retina · RCR 1.2 · 16 citations - Autoantibodies in Melanoma-Associated Retinopathy Recognize an Epitope Conserved Between TRPM1 and TRPM3.
2017 · Invest Ophthalmol Vis Sci · RCR 1.2 · 24 citations - Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy.
2020 · PLoS One · RCR 1 · 16 citations - TRPM1 Autoantibodies in Melanoma Patients Without Self-Reported Visual Symptoms.
2019 · Invest Ophthalmol Vis Sci · RCR 0.9 · 14 citations - Clinical Findings of Melanoma-Associated Retinopathy with anti-TRPM1 Antibody.
2021 · Case Rep Ophthalmol Med · RCR 0.7 · 7 citations - A case of melanoma-associated retinopathy with autoantibodies against TRPM1.
2020 · Doc Ophthalmol · RCR 0.6 · 8 citations - Degeneration of retinal on bipolar cells induced by serum including autoantibody against TRPM1 in mouse model of paraneoplastic retinopathy.
2013 · PLoS One · RCR 0.6 · 17 citations - Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: a novel approach.
2013 · Ophthalmology · RCR 0.6 · 17 citations - Melanoma-associated retinopathy with anti-TRPM1 autoantibodies showing concomitant Off-bipolar cell dysfunction.
2022 · Doc Ophthalmol · RCR 0.5 · 5 citations - Choroidal atrophy in a patient with paraneoplastic retinopathy and anti-TRPM1 antibody.
2014 · Clin Ophthalmol · RCR 0.5 · 11 citations - Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy.
2014 · Jpn J Ophthalmol · RCR 0.5 · 12 citations - Broad locations of antigenic regions for anti-TRPM1 autoantibodies in paraneoplastic retinopathy with retinal ON bipolar cell dysfunction.
2021 · Exp Eye Res · RCR 0.4 · 5 citations - Anti-TRPM1 antibodies in patients with retinal degeneration.
2018 · Clin Exp Ophthalmol · RCR 0.2 · 4 citations - Anti-TRPM1 autoantibodies.
2019 · Clin Exp Ophthalmol · RCR 0.1 · 1 citations - Alternative methods to detect anti-TRPM1 antibodies.
2019 · Clin Exp Ophthalmol - Correction: Identification and characterization of novel TRPM1 autoantibodies from serum of patients with melanoma-associated retinopathy.
2020 · PLoS One - Case Report: Longitudinal Evaluation and Treatment of a Melanoma-Associated Retinopathy Patient.
2024 · Res Sq - Electronegative ERG in association with probable TRPM1-related cancer associated retinopathy: a case report.
2026 · Doc Ophthalmol
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.07
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.13
- DepMap mean gene effect
- -0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- calcium ion import across plasma membrane
- calcium ion transmembrane transport
- calcium ion transport
- cellular response to light stimulus
- G protein-coupled glutamate receptor signaling pathway
- monoatomic cation transmembrane transport
- protein tetramerization
- visual perception
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TRPM1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TRPM1 as an antibody target. Whether an autoantibody or antibody against TRPM1 could matter depends on whether native TRPM1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TRPM1 is annotated at the cell surface, where native TRPM1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TRPM1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...